MEMORY & I/O SYSTEMS Timers // Create specified ms/us of delay using built-in timer #include void delaymicros(int micros) { if (micros > 1000) { // delaymicros(1000); delaymicros(micros-1000); } else if (micros > 6){ TMR1 = 0; // T1CONbits.ON = 1; // PR1 = (micros-6)*20; // // IFS0bits.T1IF = 0; // while (!IFS0bits.T1IF); // } } avoid timer overflow reset timer to 0 turn timer on 20 clocks per microsecond Function has overhead of ~6 us clear overflow flag wait until overflow flag set void delaymillis(int millis) { while (millis--) delaymicros(1000); // repeatedly delay 1 ms } // until done Chapter 8 <82>
View full slide show




MARRIOTT INTERNATIONAL SELECTS CLOUDBASED MICROS OPERA AS ITS NEXTGENERATION PROPERTY MANAGEMENT SYSTEM FOR ALL NORTH AMERICA PROPERTIES Columbia, MD – April 25, 2013—MICROS Systems, Inc. (NASDAQ:MCRS), a leading provider of information technology solutions for the hospitality and retail industries, is pleased to announce that Marriott International has expanded its partnership with MICROS by selecting the hosted MICROS OPERA Property Management System (PMS) as the property management system (PMS) to be used in all Marriott brands worldwide. Under the new partnership agreement, Marriott will deploy MICROS hosted OPERA PMS.
View full slide show




03/18/19 18:35 15 Traffic Mining Results 1: TCP,INPUT,129.110.96.117,ANY,*.*.*.*,80,DENY 2: TCP,INPUT,*.*.*.*,ANY,*.*.*.*,80,ACCEPT 3: TCP,INPUT,*.*.*.*,ANY,*.*.*.*,443,DENY 4: TCP,INPUT,129.110.96.117,ANY,*.*.*.*,22,DENY 5: TCP,INPUT,*.*.*.*,ANY,*.*.*.*,22,ACCEPT 6: TCP,OUTPUT,129.110.96.80,ANY,*.*.*.*,22,DENY 7: UDP,OUTPUT,*.*.*.*,ANY,*.*.*.*,53,ACCEPT 8: UDP,INPUT,*.*.*.*,53,*.*.*.*,ANY,ACCEPT 9: UDP,OUTPUT,*.*.*.*,ANY,*.*.*.*,ANY,DENY 10: UDP,INPUT,*.*.*.*,ANY,*.*.*.*,ANY,DENY 11: TCP,INPUT,129.110.96.117,ANY,129.110.96.80,22,DEN Y 12: TCP,INPUT,129.110.96.117,ANY,129.110.96.80,80,DEN Y 13: UDP,INPUT,*.*.*.*,ANY,129.110.96.80,ANY,DENY 14: UDP,OUTPUT,129.110.96.80,ANY,129.110.10.*,ANY,DE NY 15: TCP,INPUT,*.*.*.*,ANY,129.110.96.80,22,ACCEPT 16: TCP,INPUT,*.*.*.*,ANY,129.110.96.80,80,ACCEPT 17: UDP,INPUT,129.110.*.*,53,129.110.96.80,ANY,ACCEPT 18: Rule 1, Rule 2: ==> GENRERALIZATION Rule 1, Rule 16: ==> CORRELATED Rule 2, Rule 12: ==> SHADOWED Rule 4, Rule 5: ==> GENRERALIZATION Rule 4, Rule 15: ==> CORRELATED Rule 5, Rule 11: ==> SHADOWED Anomaly Discovery Result
View full slide show




Trademark Information Xilinx is disclosing this Document and Intellectual Propery (hereinafter “the Design”) to you for use in the development of designs to operate on, or interface with Xilinx FPGAs. Except as stated herein, none of the Design may be copied, reproduced, distributed, republished, downloaded, displayed, posted, or transmitted in any form or by any means including, but not limited to, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of Xilinx. Any unauthorized use of the Design may violate copyright laws, trademark laws, the laws of privacy and publicity, and communications regulations and statutes. Xilinx does not assume any liability arising out of the application or use of the Design; nor does Xilinx convey any license under its patents, copyrights, or any rights of others. You are responsible for obtaining any rights you may require for your use or implementation of the Design. Xilinx reserves the right to make changes, at any time, to the Design as deemed desirable in the sole discretion of Xilinx. Xilinx assumes no obligation to correct any errors contained herein or to advise you of any correction if such be made. Xilinx will not assume any liability for the accuracy or correctness of any engineering or technical support or assistance provided to you in connection with the Design. THE DESIGN IS PROVIDED “AS IS" WITH ALL FAULTS, AND THE ENTIRE RISK AS TO ITS FUNCTION AND IMPLEMENTATION IS WITH YOU. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE NOT RELIED ON ANY ORAL OR WRITTEN INFORMATION OR ADVICE, WHETHER GIVEN BY XILINX, OR ITS AGENTS OR EMPLOYEES. XILINX MAKES NO OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, OR STATUTORY, REGARDING THE DESIGN, INCLUDING ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NONINFRINGEMENT OF THIRD-PARTY RIGHTS. IN NO EVENT WILL XILINX BE LIABLE FOR ANY CONSEQUENTIAL, INDIRECT, EXEMPLARY, SPECIAL, OR INCIDENTAL DAMAGES, INCLUDING ANY LOST DATA AND LOST PROFITS, ARISING FROM OR RELATING TO YOUR USE OF THE DESIGN, EVEN IF YOU HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE TOTAL CUMULATIVE LIABILITY OF XILINX IN CONNECTION WITH YOUR USE OF THE DESIGN, WHETHER IN CONTRACT OR TORT OR OTHERWISE, WILL IN NO EVENT EXCEED THE AMOUNT OF FEES PAID BY YOU TO XILINX HEREUNDER FOR USE OF THE DESIGN. YOU ACKNOWLEDGE THAT THE FEES, IF ANY, REFLECT THE ALLOCATION OF RISK SET FORTH IN THIS AGREEMENT AND THAT XILINX WOULD NOT MAKE AVAILABLE THE DESIGN TO YOU WITHOUT THESE LIMITATIONS OF LIABILITY. The Design is not designed or intended for use in the development of on-line control equipment in hazardous environments requiring fail-safe controls, such as in the operation of nuclear facilities, aircraft navigation or communications systems, air traffic control, life support, or weapons systems (“High-Risk Applications”). Xilinx specifically disclaims any express or implied warranties of fitness for such High-Risk Applications. You represent that use of the Design in such High-Risk Applications is fully at your risk. © 2009 Xilinx, Inc. All rights reserved. XILINX, the Xilinx logo, and other designated brands included herein are trademarks of Xilinx, Inc. All other trademarks are the property of their respective owners. FPGA and ASIC Technology Comparison - 23 © 2009 2007 Xilinx, Inc. All Rights Reserved
View full slide show




Nano Nano Nano Nano Nano milli micro 10-3 10-6 Latin micros Greek micros nano 10-9 Greek nanos pico femto atto 10-12 10-15 10-18   thousand small  dwarf Spanish pico  Danish/Norwegian femten  Danish/Norwegian atten  small quantity fifteen eighteen
View full slide show




rcTime() function // rcTime function measures decay at pin long rcTime(int pin) { pinMode(pin, OUTPUT); digitalWrite(pin, HIGH); delay(5); pinMode(pin, INPUT); digitalWrite(pin, LOW); long time = micros(); while(digitalRead(pin)); time = micros() - time; return time; } // Charge capacitor // ..by setting pin ouput-high // ..for 5 ms // Set pin to input // ..with no pullup // Mark the time // Wait for voltage < threshold // Calculate decay time // Returns decay time
View full slide show




Code for Testing QTIs int LeftQTI = 8; int RightQTI = 2; void setup() { Serial.begin(9600); } void loop() { long tLeft = rcTime(LeftQTI); long tRight = rcTime(RightQTI); Serial.print("tLeft = "); Serial.print(tLeft); Serial.println(" us"); Serial.print("tRight = "); Serial.print(tRight); Serial.println(" us"); delay(1000); } long rcTime(int pin) { // ..returns decay time pinMode(pin, OUTPUT); // Charge capacitor digitalWrite(pin, HIGH); // ..by setting pin ouput-high delay(1); // ..for 5 ms pinMode(pin, INPUT); // Set pin to input digitalWrite(pin, LOW); // ..with no pullup long time = micros(); // Mark the time while(digitalRead(pin)); // Wait for voltage < threshold time = micros() - time; // Calculate decay time return time; // Return decay time }
View full slide show




CP/M - Control Program for Micros • Gary Kildall (PL/M for 8080 @ IBM) • CP/M (Control Program for Micros) - $100 – To control disk drives – Similar to DEC commands – $800 with floppy drive & controller • Final piece of puzzle for PC • Formed (Intergalactic) Digital Research – Product CP/M 44
View full slide show




Cisco Router: Access Control Lists [wildcard] [srcport] [wildcard] [dest-port] [other-options] deny tcp any any range 135 139 log permit udp any host 220.10.5.33 eq 600 [wildcard] [port] [wildcard] [port] reflect Example: ip access-list extended FilterOut permit tcp any any eq 22 reflect ssh-filter permit tcp any any eq 80 deny tcp any any range 0 1024 deny tcp any any gt 1024 deny udp any any range 0 1024 ! ip access-list extended FilterIn evaluate ssh-filter permit tcp any any eq 80
View full slide show




Cisco Router: Access Control Lists [wildcard] [srcport] [wildcard] [dest-port] [other-options] deny tcp any any range 135 139 log permit udp any host 220.10.5.33 eq 600 [wildcard] [port] [wildcard] [port] reflect Example: ip access-list extended FilterOut permit tcp any any eq 22 reflect ssh-filter permit tcp any any eq 80 deny tcp any any range 0 1024 deny tcp any any gt 1024 deny udp any any range 0 1024 ! ip access-list extended FilterIn evaluate ssh-filter permit tcp any any eq 80
View full slide show




Disclosure Statements This presentation has been prepared by NantHealth, Inc. (the “Company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any information or statement after the date of this presentation as a result of new information, subsequent events or any other circumstances. These materials and related materials and discussions may contain forward-looking statements that are based on the Company’s current expectations, and projections and forecasts about future events and trends that the Company believes may affect its business, financial condition, operating results and growth prospects. Forward-looking statements are subject to substantial risks, uncertainties and other factors, including but not limited to (1) the structural change in the market for healthcare in the United States, including uncertainty in the healthcare regulatory framework and regulatory developments in the United States and foreign countries; (2) the evolving treatment paradigm for cancer, including physicians’ use of molecular information and targeted oncology therapeutics and the market size for molecular information products; (3) physicians’ need for precision medicine products and any perceived advantage of our solutions over those of our competitors, including the ability of our comprehensive platform to help physicians treat their patients’ cancers; (4) our ability to generate revenue from sales of products enabled by our molecular and biometric information platforms to physicians in clinical settings; (5) our ability to increase the commercial success of our sequencing and molecular analysis solution; (6) our plans or ability to obtain reimbursement for our sequencing and molecular analysis solution, including expectations as to our ability or the amount of time it will take to achieve successful reimbursement from third-party payors, such as commercial insurance companies and health maintenance organizations, and government insurance programs, such as Medicare and Medicaid; (7) our ability to effectively manage our growth, including the rate and degree of market acceptance of our solutions; and (8) our ability to offer new and innovative products and services, attract new partners and clients, estimate the size of our target market, and maintain and enhance our reputation and brand recognition. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No representation or warranty, express or implied, is given as to the completeness or accuracy of the information or opinions contained in this document and neither the Company nor any of its directors, members, officers, employees, agents or advisers accepts any liability for any direct, indirect or consequential loss or damage arising from reliance on such information or opinions. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. We own or have rights to trademarks and service marks that we use in connection with the operation of our business. NantHealth, Inc. and our logo as well as other protected brands. Solely for convenience, our trademarks and service marks referred to in this presentation are listed without the (sm) and (TM) symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. Additionally, we do not intend for our use or display of other companies’ trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. We have indicated with (TM) symbols where these third party trademarks are referred to in this presentation. This presentation includes certain financial measures not based on accounting principles generally accepted in the United States, or non-GAAP measures. These non-GAAP measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. Confidential Copyright © Do not distribute 6
View full slide show




Remember any of these Micros?
View full slide show